EP2239267B1 - Peptide marqueur et son utilisation - Google Patents

Peptide marqueur et son utilisation Download PDF

Info

Publication number
EP2239267B1
EP2239267B1 EP08871991.9A EP08871991A EP2239267B1 EP 2239267 B1 EP2239267 B1 EP 2239267B1 EP 08871991 A EP08871991 A EP 08871991A EP 2239267 B1 EP2239267 B1 EP 2239267B1
Authority
EP
European Patent Office
Prior art keywords
gly
gln
tyr
antibody
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP08871991.9A
Other languages
German (de)
English (en)
Other versions
EP2239267A1 (fr
EP2239267A4 (fr
Inventor
Junichi Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of EP2239267A1 publication Critical patent/EP2239267A1/fr
Publication of EP2239267A4 publication Critical patent/EP2239267A4/fr
Application granted granted Critical
Publication of EP2239267B1 publication Critical patent/EP2239267B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Definitions

  • the present invention relates to a tag peptide and use thereof, and in particular relates to a tag peptide that can be applied to protein purification, detection or quantification, a tag peptide fusion protein having the tag peptide linked thereto, a polynucleotide encoding the tag peptide, a recombinant vector containing the polynucleotide, a protein purification method, and a kit using the same.
  • Affinity chromatography is one of the most powerful means for protein purification.
  • a method involving attaching a histidine-containing peptide of 6 to 10 residues (histidine tag) to the N or C terminus of proteins and using the interaction of the histidine tag and a metal such as nickel is known.
  • a method using the interaction of a tag peptide (peptide tag) and an antibody thereagainst is also known (for example, nonpatent literatures 1 and 2).
  • a FLAG (registered trademark) system commercially available from Sigma is used extensively. This technique, in which a FLAG peptide and an antibody thereagainst (antibodies M1 and M2, etc.) are used, is currently considered the most excellent in specificity.
  • the FLAG (registered trademark) system is so expensive that it may be limitedly used in terms of cost.
  • WO 96/02641 A2 relates to diagnostic, prophylactic and therapeutic materials and methods based on polynucleotides and polypeptides which are characteristics of synovial sarcoma and specific binding members therefor.
  • Lin Zhang et al. (Molecular Biotechnology, vol. 19, 2001, pages 313-321 ) describe multiple tandem epitope tagging for enhanced detection of protein expressed in mammalian cells.
  • An object of the present invention is to provide a novel tag peptide that can be used for a system which enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner, and to provide a tag peptide fusion protein in which such a tag peptide is linked to a protein. Another object thereof is to provide a polynucleotide encoding the tag peptide, and a recombinant vector containing the polynucleotide. Yet another object thereof is to provide a protein purification method which can be performed in an inexpensive and simple manner using the interaction of the tag peptide and an antibody thereagainst, and to provide a kit for protein expression using the above interaction.
  • P20.1 antibody a certain antibody
  • P4 peptide a peptide having a recognition sequence for the antibody
  • the inventor also found that the P20.1 antibody recognizes the 6 residues (Gly-Tyr-Pro-Gly-Gln-Val: SEQ ID NO: 1) from the C terminus of the N-terminal 20 residues of the human thrombin acceptor PAR4, and that among the 6 residues, tyrosine, glycine and glutamine at position 2, 4 and 5 from the N terminus, respectively, are indispensable for the interaction with the antibody.
  • a tag peptide having multiple repeats of the 6-residue sequence hereinafter sometimes referred to as "P4 sequence" has an increased affinity for the P20.1 antibody. In this way, the inventor reached the idea that the use of the tag peptide having such a repeated sequence and the P20.1 antibody enables proteins expressed from cloned genes to be highly purified in a single step.
  • the inventor further examined the conditions for affinity purification, and then found that the interaction of the tag peptide having the above-mentioned repeated sequence and the P20.1 antibody can be easily disrupted by water-miscible organic solvents such as polyols.
  • the purification system of the present invention allows use of water-miscible organic solvents such as polyols as an eluent, and thereby protein purification can be achieved under mild conditions. Therefore, objective proteins can be purified without any denaturation or the like, and advantageously this purification system can be repeatedly used since antibodies hardly deteriorate.
  • eluent refers to the substance that has an action by which the antibody and the tag peptide dissociate.
  • the inventor also found that by use of the tag peptide having the above-mentioned repeated sequence and the antibody, sufficient amounts of high-quality recombinant proteins that are suitable for X-ray crystallography can be obtained in a single purification step.
  • proteins that are extremely pure, chemically uniform and 100% biologically active need to be prepared in units of milligrams.
  • the technique of the present invention is preferable for preparation of proteins for X-ray crystallography.
  • the inventor found that the tag peptide having the above-mentioned repeated sequence and the antibody can be used for protein detection and quantification.
  • the present inventor further studied and then completed the present invention.
  • the present invention relates to the following (1) to (9).
  • tag peptide fusion proteins having the above-mentioned tag peptide linked thereto can be highly purified in an easy manner using the interaction of the tag peptide and an antibody thereagainst. Therefore, according to the present invention, even an unskilled person can easily purify unstable recombinant proteins that are expressed from cloned genes in only small amounts.
  • the eluent used for purification in the present invention is relatively inexpensive and allows repeated use of antibodies, cost cutting in protein purification can be achieved.
  • the use of the tag peptide and an antibody thereagainst enables efficient detection and/or quantification of tag peptide fusion proteins having the tag peptide linked thereto.
  • the tag peptide of the present invention has an amino acid sequence represented by the following formula (I): X 1 -Tyr-X 2 -Gly-Gln-X 3 (I)
  • the tag peptide of the present invention has an amino acid sequence represented by the above formula (I) (hereinafter sometimes referred to as "sequence (I)”) and has amino acid sequences each represented by the following formula (IV): (Tyr-X 2 -Gly-Gln) (IV) (wherein X 2 represents any amino acid residue) at two or more sites.
  • sequence (IV) amino acid sequences each represented by formula (IV) (hereinafter sometimes referred to as "sequence (IV)”) are located at two sites so that they flank two amino acid residues X 3 and X 1 .
  • sequence (IV) one sequence (I) in which X 1 is Gln and X 3 is Tyr is included.
  • sequences (IV) are located at least two sites of a tag peptide having at least one sequence (I) and the interval or location of the sequences (IV) are not limited.
  • X 1 is not particularly limited, but glycine is preferable, for example.
  • X 2 is preferably an amino acid having a small side chain, such as serine, valine, cysteine, alanine, threonine, glutamic acid, glycine and aspartic acid, or proline. More preferred is proline.
  • X 3 is preferably a hydrophobic amino acid, and examples thereof include valine, leucine, isoleucine, alanine, phenylalanine, tyrosine, tryptophan, proline and methionine. Inter alia, valine is preferable.
  • the sequence (I) is particularly preferably Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 1). Constituent amino acids of the tag peptide of the present invention are all L-amino acids.
  • the tag peptide preferably comprises sequences (I) at two or more sites, and more preferably comprises an amino acid sequence having 2 repeats or more of sequence (I).
  • the number of the sequence (I) is not limited.
  • the tag peptide comprises an amino acid sequence having 2 repeats or more of sequence (I)
  • the repeat number is not limited. It is confirmed that the tag peptide of the present invention has a higher affinity for an antibody thereagainst as the repeat number of sequence (I) increases.
  • the maximum number of amino acid residues of the tag peptide of the present invention is not particularly limited, but in respect of practical use, preferably 50 or less, more preferably 40 or less and even more preferably 30 or less.
  • the tag peptide of the present invention comprises an amino acid sequence having 3 to 5 repeats of the following repeat unit: Tyr-Pro-Gly-Gln (SEQ ID NO: 18).
  • the tag peptide of the present invention can be linked to any protein by a genetic engineering method, and thereby can be formed into a fusion protein of the tag peptide and any protein.
  • the tag peptide may be linked to the N or C terminus of any protein.
  • Such a tag peptide fusion protein in which the tag peptide is linked to the N or C terminus of any protein can be highly purified in a single step by use of an antibody that specifically binds to the tag peptide. Using the antibody, detection of the tag peptide fusion protein, quantification thereof, etc. can also be performed.
  • the tag peptide of the present invention can be chemically linked to any substance. Using an antibody that specifically binds to the tag peptide of the present invention, a substance that the tag peptide is chemically linked to can be highly purified in a simple manner, and its detection, quantification, etc. can also be performed.
  • the substance that the tag peptide is chemically linked to is not limited, and examples thereof include proteins, nucleic acids, saccharides, organic polymers and metals.
  • the tag peptide fusion protein of the present invention refers to a fusion protein of the tag peptide of the present invention set forth above (hereinafter referred to simply as "tag peptide") and any protein, in which they are linked to each other.
  • the tag peptide may be linked to the N or C terminus of any protein.
  • Such a tag peptide fusion protein in which the tag peptide is linked to the N or C terminus of any protein can be highly purified in a single step by use of an antibody that specifically binds to the tag peptide.
  • the tag peptide fusion protein of the present invention can be prepared by a known gene-recombination technology. The outline is illustrated as follows.
  • a polynucleotide encoding the tag peptide of the present invention is synthesized by a known method.
  • the polynucleotide may be DNA or RNA, and is preferably DNA.
  • DNA it can be synthesized with a DNA synthesizer.
  • DNA fragments separately synthesized may be ligated.
  • the DNA sequence for the tag peptide may be diverse due to degeneracy of the genetic code, and is not particularly limited as long as a peptide expressed from the DNA sequence has an amino acid sequence of the tag peptide of the present invention.
  • DNA encoding the P4 sequence the DNA sequence represented by SEQ ID NO: 9 can be used, for example.
  • SEQ ID NO: 11 is an example of DNA encoding a tag peptide consisting of the amino acid sequence having 3 repeats of the P4 sequence
  • SEQ ID NO: 13 is an example of DNA encoding a tag peptide consisting of the amino acid sequence having 5 repeats of the P4 sequence.
  • DNA encoding an objective protein is ligated to the 3'- or 5'-terminus of the synthesized DNA encoding the tag peptide.
  • DNA encoding the objective protein is prepared by PCR or other methods, the use of the DNA encoding the tag peptide as a 3'- or 5'-end primer gives the gene of the objective protein ligated with the DNA encoding the tag peptide as a PCR product.
  • a spacer peptide may be inserted between the objective protein and the tag peptide.
  • the spacer peptide may be any peptide that does not bind to or associate with the antibody against the tag peptide of the present invention, which is described below, and does not impair the interaction of the tag peptide and the antibody.
  • Examples of the spacer peptide include peptides having a protease recognition sequence.
  • DNA preparation is performed such that DNA encoding the spacer peptide is ligated between the DNA encoding the tag peptide and the DNA encoding the object protein.
  • the obtained DNA which comprises DNA encoding the tag peptide and DNA encoding the objective protein, is appropriately inserted into an expression vector.
  • the vector is not particularly limited, and known expression vectors derived from bacteria, yeasts, viruses or the like can be preferably used.
  • a promoter in the expression vector is any promoter compatible with hosts used for expression.
  • the expression vector may further comprise an enhancer, a splicing signal, a poly A addition signal, a selection marker and a replication origin.
  • the thus-obtained expression vector is introduced into host cells.
  • the host cell is not particularly limited, and examples thereof include microorganisms such as Escherichia coli and yeasts; and animal cells. Preferred are animal cells.
  • a method of introducing the expression vector into host cells can be appropriately selected from known transformation methods depending on the kind of host cells.
  • the obtained recombinant microorganisms or cells are cultured in an appropriate medium for expression of the tag peptide fusion protein.
  • the tag peptide fusion protein may be purified from the recombinant microorganisms or cells, or culture media therefor in a single step by use of an antibody described below.
  • the present invention also includes the polynucleotide encoding the tag peptide, and a recombinant vector containing the polynucleotide, both of which are illustrated in the above preparation of the tag peptide fusion protein.
  • the recombinant vector of the present invention is not limited to recombinant vectors that enable expression of the fusion protein of the tag peptide and the objective protein (tag peptide fusion protein), and includes vectors just containing the polynucleotide encoding the tag peptide.
  • the present invention provides a purification method for proteins using a monoclonal antibody produced by mouse-mouse hybridoma P20.1 (internationally deposited at International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (central 6, 1-1-1, Higashi, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) under the accession number FERM BP-11061 on December 11, 2007).
  • the purification method for proteins comprises the following steps (i) to (iii) :
  • a method of preparing the mixture is not particularly limited.
  • the objective protein i.e., the tag peptide fusion protein
  • the tag peptide fusion protein is present in cells, lysis, homogenization, etc. of cultured recombinant microorganisms or cells by a known method gives the desired mixture (cell lysate) containing the tag peptide fusion protein and another substance.
  • the tag peptide fusion protein is present in an insoluble fraction such as an inclusion body, solubilization and subsequent refolding (unwinding) of proteins, etc. may be appropriately performed before the step (ii).
  • the supernatant of the culture medium is collected for use as a mixture in the step (ii). Solids contained in the cell lysate or supernatant are removed by centrifugation, and if needed the pH of the lysate or supernatant is adjusted to neutrality (7 to 8), but addition of salts or other substances is not particularly needed.
  • the concentration of the objective protein in the mixture is preferably 0.2 ⁇ g/mL or more.
  • an immobilized antibody i.e., a monoclonal antibody produced by mouse-mouse hybridoma P20.1 having accession number FERM BP11061 immobilized onto a support
  • the support onto which the antibody is immobilized is not particularly limited as long as the effect of the present invention is achieved, and known supports can be used.
  • Sepharose GE Healthcare
  • Affi-Gel BIO-RAD
  • a method of immobilizing the antibody onto the support is not particularly limited and can be appropriately selected depending on the kind of the support, etc.
  • the antibody is dialyzed against a coupling buffer and then mixed with CNBr-activated Sepharose (GE Healthcare) at room temperature for about 1 to 2 hours.
  • Examples of the purification method for proteins in the present invention include both of a column method using the above-mentioned immobilized antibody packed into a column, and a batch method involving mixing the immobilized antibody with a sample for complex formation in a suspension.
  • the immobilized antibody is packed into a column
  • the mixture prepared in the step (i) is loaded onto the column, and thereby the antibody of the present invention acts on the tag peptide.
  • the tag peptide and the antibody bind to each other and thereby a complex of the tag peptide fusion protein and the antibody is formed.
  • about 100 ⁇ L of the immobilized antibody is gently mixed with 10 mL of a sample solution. After a complex of the tag peptide fusion protein and the antibody is formed in the mixture, the mixture is packed into a column.
  • the water-miscible organic solvent is allowed to act on the complex obtained in the step (ii) for release of the tag peptide fusion protein from the antibody. Namely, by an action of the eluent on the complex, the antibody and the tag peptide dissociate, and the tag peptide fusion protein bound to the immobilized antibody via the tag peptide is released from the antibody.
  • water-miscible organic solvent any substance that has an action to disrupt the bond between the tag peptide and the antibody can be used.
  • water-miscible organic solvents include polyols. Inter alia, particularly preferred is propylene glycol or dimethyl sulfoxide. Ethylene glycol can also be used.
  • the water-miscible organic solvent When the water-miscible organic solvent is allowed to act on the complex of the tag peptide fusion protein and the antibody, it is preferable that the water-miscible organic solvent is dissolved in water or an appropriate buffer solution and that the resulting water-miscible organic solvent solution is loaded onto the column.
  • the tag peptide fusion protein released from the antibody by an action of the water-miscible organic solvent is eluted together with the water-miscible organic solvent solution from the column.
  • Water or a buffer solution may be selected depending on the kind of the protein.
  • the content of the water-miscible organic solvent in the water-miscible organic solvent solution is appropriately varied with the kind of the water-miscible organic solvent or the objective protein, i.e., the tag peptide fusion protein, or the like.
  • the blending ratio of the water-miscible organic solvent is preferably about 40% (v/v) or more relative to the total volume of water or a buffer solution, and the water-miscible organic solvent, the total volume being set to 100%.
  • the volume ratio of water or a buffer solution to the water-miscible organic solvent is preferably about 60:40 to 40:60.
  • a salt may be added in order to stabilize the tag peptide fusion protein to be obtained.
  • the kind of the salt can be determined according to the kind of the protein, etc., and is not particularly limited.
  • the concentration of the salt can be appropriately adjusted depending on the kind of the protein, and is not particularly limited.
  • the immobilized antibody is washed with the water-miscible organic solution solution and thereby can be used repeatedly.
  • the purification method for proteins of the present invention may further comprises a step (iv) of cleaving the tag peptide from the tag peptide fusion protein after the steps (i) to (iii) are all completed.
  • a protease that recognizes the protease recognition sequence is allowed to act on the purified fusion protein under appropriate conditions, and thereby the object protein without the tag peptide can be obtained.
  • the tag peptide and the antibody specifically interact with each other and the interaction is easily disrupted by an action of the water-miscible organic solvent.
  • the tag peptide fusion protein can be highly purified in a single step.
  • the purification can be performed without any denaturation of the objective fusion protein or the antibody since a water-miscible organic solvent is used as the eluent in the purification method. Therefore, according to the present invention, sufficient amounts of high-quality recombinant proteins that are suitable for X-ray crystallography can be obtained in a single purification step.
  • proteins that are extremely pure, chemically uniform and 100% biologically active need to be prepared in units of milligrams.
  • the technique of the present invention is preferable for preparation of proteins that can be subjected to X-ray crystallography.
  • the immobilized antibody can be repeatedly used for purification.
  • the present inventor repeatedly used an immobilized antibody, i.e., the P20.1 antibody immobilized onto Sepharose, for purification of the tag peptide fusion protein (GFPuv-P4x3 fusion protein) of the present invention and examined the effect of its repeated use on the purification.
  • the inventor confirmed that even though the immobilized antibody was repeatedly used 21 times, the yield of the fusion protein declined only slightly (see [10] of Examples).
  • water-miscible organic solvents used as the eluent are relatively inexpensive, the purification method of the present invention enables proteins to be purified in an inexpensive and simple manner.
  • the present invention provides a kit for expressing a tag peptide fusion protein having the above described tag protein, comprising the recombinant vector of the present invention.
  • a kit for expressing a tag peptide fusion protein having the above described tag protein comprising the recombinant vector of the present invention.
  • protein expression can be simply performed.
  • the kit for protein expression essentially comprises the recombinant vector of the present invention.
  • the recombinant vector of the kit is preferably provided in such a form that users of the kit can prepare an expression vector for a tag peptide fusion protein in which the tag peptide of the present invention and an objective protein are linked to each other by inserting DNA encoding the objective protein into vectors. Then, the users can simply achieve expression of the desired protein, i.e., the tag peptide fusion protein by introducing the prepared expression vector into appropriate host cells and culturing the host cells.
  • the kit may further comprises a secondary antibody, a reaction buffer solution, a substrate, an instruction manual, etc. in addition to the recombinant vector of the present invention.
  • the tag system of the present invention is advantageous in respect of the followings.
  • An anti-PAR4 peptide antibody was prepared by a usual method as follows.
  • a peptide having the following sequence (SEQ ID NO: 2) NH 2 -GGDDSTPSILPAPRGYPGQVC-COOH, which corresponds to the N-terminal 20 residues of the human thrombin receptor PAR4, was synthesized by the Fmoc solid phase method.
  • the above-mentioned peptide was purified by reversed phase HPLC and then coupled to keyhole limpet hemocyanin (KLH), which is a carrier protein, via a cysteine (Cys) residue and the resulting complex was used as an immunogen.
  • KLH keyhole limpet hemocyanin
  • a Balb/c mouse was immunized with the resulting peptide-KLH complex and an adjuvant, and antibody titer measurement was performed by the ELISA method. Repeated immunization (25 ⁇ g ⁇ 5) gave a high titer antibody. Spleen cells of this mouse were used for cell fusion.
  • B cells were separated from the spleen cells and fused with mouse myeloma cells (SP2/0 cell line) by the polyethylene glycol method, and then cell culture was performed in an HAT selection medium.
  • ELISA-based screening was performed using the supernatants of wells where a colony was found, and strongly positive samples were selected as a candidate for secondary screening.
  • a fusion protein (PAR4-Fn) described later was used as an antigen.
  • PAR4-Fn fusion protein
  • the clone was subjected to cloning by limiting dilution, and finally, mouse-mouse hybridoma P20.1 was established (internationally deposited at International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (central 6, 1-1-1, Higashi, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan ) under the accession number FERM BP-11061 on December 11, 2007).
  • the Fab fragment of the P20.1 antibody was prepared by use of an Immunopure Fab preparation kit commercially available from PIERCE.
  • the purified P20.1 antibody IgG was digested with immobilized papain at 37°C for 16 hours, the digest was loaded onto protein A sepharose, and unbound digest was subjected to gel filtration for purification.
  • the purified P20.1 antibody (about 30 mg) was dialyzed against a coupling buffer (0.1 M NaHCO 3 , 0.3 M NaCl, pH 8.3) and then mixed with CNBr-activated Sepharose 4B (GE Healthcare), which was washed with 1 mM hydrochloric acid in advance, at room temperature for 1 hour, to give an antibody immobilized onto Sepharose. Unreacted active groups were blocked with 0.1 M Tris, and nonspecifically bound antibodies were removed with 0.1 M Gly-HCl, pH 2.2. The results of qualitative analysis of the unbound antibody showed that about 2 mg of the P20.1 antibody per 1 mL of Sepharose resin was able to be immobilized.
  • a coupling buffer 0.1 M NaHCO 3 , 0.3 M NaCl, pH 8.3
  • CNBr-activated Sepharose 4B GE Healthcare
  • constructs for 6 different tag peptide fusion proteins (6 sequences from the top in Fig. 1 ) were prepared. Each fusion protein has a different length of the P4 peptide sequence (the whole or a part of the N-terminal 20 residues of PAR4) attached to the N or C terminus of the above domain.
  • the insert was prepared by extension PCR and then was inserted into the NdeI-BamHI site of the expression vector pET11c (Novagen).
  • Constructs for mutants (Ala mutants) (6 sequences from the bottom in Fig. 1 ) were prepared by use of Quick Change Mutagenesis kit (Stratagen). Each mutant has substitution of alanine for a different amino acid of the C-terminal 6 residues of the P4 peptide sequence.
  • Escherichia coli BL21 (DE3) cells were transformed with the respective constructs described above, and induced expression of the corresponding tag peptide fusion proteins was achieved by a usual method.
  • Each of the produced tag peptide fusion proteins was purified from Escherichia coli lysate by anion exchange chromatography.
  • a vector for animal cells to express a fusion protein of human growth factor (hGH) and the C domain of the human fibrinogen ⁇ chain has been already reported ( Xiao et al. Nature 432, 59-67, 2004 ).
  • DNA encoding a peptide having 1, 3 or 5 repeats of the 6-residue peptide derived from the P4 peptide (GYPGQV: P4 sequence (SEQ ID NO: 1) was attached by extension PCR, to give the desired DNA.
  • the vector for animal cells to express the P4-sequence-tagged fusion protein of human growth factor (hGH) and the C domain of the human fibrinogen ⁇ chain is shown in Fig.
  • Fig. 2 (b) shows constructs having 1, 3 or 5 repeats of the P4 sequence (6 residues) downstream of the fibrinogen ⁇ chain fragment ( ⁇ C) following the biotin acceptor sequence (BAS) bound to the minigene of hGH.
  • a partial sequence of DNA encoding the tag peptide fusion protein having P4 sequence attached thereto is shown in SEQ ID NO: 15 and Fig. 3 .
  • the bases at nucleotide positions 1 to 2100 and 3121 to 5424 are omitted from the entire 5424-base DNA encoding the tag peptide fusion protein having the P4 sequence attached thereto (hGH-BAS- ⁇ C-P4).
  • the DNA sequence represented by SEQ ID NO: 15 is the base sequence corresponding to nucleotide positions 2101 to 3120 of the 5424-base DNA encoding hGH-BAS- ⁇ C-P4.
  • the underlined part is a hGH sequence.
  • the shaded region indicates a His tag sequence.
  • the region in italic type indicates a linker.
  • the thick underlined part indicates a TEV protease site.
  • the part with a dashed line is a BAS sequence.
  • the region in a bold letter is a P4 tag.
  • the boxed amino acid sequence is a P4 sequence.
  • the unmarked region indicates a fibrinogen ⁇ C region.
  • the DNA sequence encoding a tag peptide consisting of the amino acid sequence having 3 repeats of the P4 sequence (P4x3) is shown in SEQ ID NO: 11.
  • the DNA sequence encoding a tag peptide consisting of the amino acid sequence having 5 repeats of the P4 sequence (P4x5) is shown in SEQ ID NO: 13.
  • a partial DNA sequence of the construct having the sequence P4x3 attached thereto is shown in Fig. 4 (a) .
  • a partial DNA sequence of the construct having the sequence P4x5 attached thereto is shown in Fig. 4 (b) .
  • the bases at nucleotide positions 1 to 3000 and 3181 to 5460 are omitted from the entire 5460 bases.
  • Fig. 4 (b) the bases at nucleotide positions 1 to 3000 and 3181 to 5496 are omitted from the entire 5496 bases.
  • the region in a bold letter is a P4 tag
  • the boxed amino acid sequence is a P4 sequence
  • the unmarked region is a fibrinogen ⁇ C region.
  • Each of the prepared plasmids was transfected into a human fibroblast cell line HEK293T, which was then cultured in a DMEM medium supplemented with 10% fetal bovine serum. From the cell culture supernatant, each human growth factor/human fibrinogen/tag peptide fusion protein was purified by Ni-NTA agarose (Qiagen) chromatography. For detection of this tag peptide fusion protein, a mouse anti-hGH monoclonal antibody HGH-B (American Type Culture Collection) and an antiserum (rabbit) against the biotin acceptor sequence (BAS) were used.
  • HGH-B American Type Culture Collection
  • BAS biotin acceptor sequence
  • the minimum peptide sequence required for recognition by the P20.1 antibody was identified by the ELISA method using various kinds of P4-Fn proteins prepared in the above (2-1).
  • the protocol is as follows.
  • the ELISA results showed that the P4 peptide, whether fused to the N or C terminus of the Fn, can be recognized by the P20.1 antibody.
  • the ELISA results of 5 different tag peptide fusion proteins having the P4 peptide attached to the N terminus of the Fn are shown in Fig. 5 .
  • These results showed that the C-terminal 6-residue region of the P4 peptide (GYPGQV: P4 sequence (SEQ ID NO: 1)) is enough for recognition by the P20.1 antibody.
  • Each mutant having substitution of Ala for a different amino acid of the 6 residues was similarly examined and the results are shown in Fig. 6 .
  • Fig. 6 In Fig.
  • G, Y, P, G, Q or V represents a modified fusion protein having substitution of alanine for the corresponding amino acid.
  • Y2, G4 and Q5 are essential, but the substitution of Ala for G1, P3 or V6 does not change the responsiveness.
  • the surface plasmon resonance analysis using Biacore was performed.
  • the P4(20)-Fn (see Fig. 1 ) purified in the (2-1) was biotinylated and then captured by a streptavidin-immobilized sensor chip, a purified P20.1 antibody was allowed to flow over the prepared sensor chip at various concentrations. The results are shown in Fig. 7 and Table 1.
  • the P20.1 antibody showed the apparent dissociation equilibrium constant (Kd) of about 3.4 nM in respect to the affinity for the P4(20)-Fn.
  • the P4(20)-Fn (0.12 to 0.87 pmol/lane) purified in the (2-1) was separated by SDS electrophoresis, transferred on a PDVF membrane, allowed to react with 1 ⁇ g/mL of the P20.1 antibody, and then detected by use of a peroxidase-labeled anti-mouse IgG and a chemiluminescence substrate.
  • the results are shown in Fig. 9 .
  • the P20.1 antibody can achieve the detection of the P4 peptide fusion protein of about 0.2 pmol in the western blotting analysis.
  • the phage display method was employed.
  • the outline of the phage display method is shown in Fig. 10 .
  • the phagemid shown in Fig. 11 was constructed for insertion of the randomized 7-amino-acid peptide library (all of them have Tyr2 and Gln5 in common) into the N terminus of the gIII coat protein of M13 phage. As a result, the phage library of 10 7 members was obtained.
  • the P20.1 antibody accepts a hydrophobic amino acid at position 6, and has no particularly strong selectivity to an amino acid residue at position 1 or 7. Namely, it can be said that the P20.1 antibody generally has a high affinity for the following peptide sequence: X1-Tyr2-Pro3-Gly4-Gln5-X6 (wherein X1 is any amino acid residue; Pro3 may be an amino acid having a small side chain, such as S, V, C, A, T, E, G and D; and X6 is any hydrophobic amino acid).
  • the structure determination of the P20.1 antibody Fab fragment requires its exact amino acid sequence.
  • sequence determination the total RNA was extracted from the mouse-mouse hybridoma P20.1 (FERM BP-11061) by use of Total RNA Isolation System (Promega). The volume and concentration of the extracted total RNA were 100 ⁇ L and 22.7 ng/ ⁇ L, respectively. Using this RNA as a template, RT-PCR was performed with Mouse Ig-Primer Set (Novagen). The amplified PCR product was ligated to the pDrive Cloning Vector (QIAGEN PCR Cloning Kit), which was then used for transformation of Escherichia coli DH5a. The transformants were cultured on LB plates supplemented with ampicillin, X-gal and IPTG, to form colonies.
  • the DNA sequencing of the variable region was performed using the primers for RT-PCR described above. Based on the determined sequence, internal primers were designed and then used for sequencing of the constant region in succession.
  • the obtained DNA/amino acid sequences are shown in the SEQ ID NOS: 3 and 5 of the appended sequence list, as well as Figs. 13 and 14 .
  • SEQ ID NO: 3 and Fig. 13 show the DNA/amino acid sequences of the heavy chain variable region of the P20.1 antibody Fab fragment.
  • SEQ ID NO: 5 and Fig. 14 show the DNA/amino acid sequences of the light chain variable region thereof.
  • Fig. 15 The obtained protein crystal is shown in Fig. 15 .
  • the inside of the left circle is a schematic view showing the crystallized complex of the P20.1 antibody Fab fragment and the P4(C8) peptide, and the right image is an enlarged view of the crystallized complex.
  • the 3D structure of the above complex was determined by the molecular replacement method.
  • the Monoclonal Antibody 2D12.5 Fab Complexed with Gd-DOTA (PDB ID: 1NC4) was used. (Like the P20.1 antibody, the antibody 2D12.5 is an IgG1 isotype and has ⁇ light chains.) As a result, the structure of two Fab molecules in a unit cell was determined.
  • the primary structure of the P20.1 antibody determined in the (5-1) was used for phase improvement and structure refinement. Automated modeling was performed by ARP/wARP using this primary structure data and the molecular replacement solutions. As a result, the model for 736 residues of 884 residues was built, and the structures of the side chains of 650 residues of them were also assigned to the model. Based on the improved map, model fitting was performed for structure refinement. The statistics are shown in Table 3. Table 3 Refinement statistics Resolution limit 83.3 - 1.80 R work 18.6 R free 21.2 Non-H atoms 6819 Fab (No. residues) 6357 (832) C8 peptide (No.
  • Fig. 16 is an enlarged view showing the entire structure and antigen recognition site of one of the two complexes.
  • the determined 3D structure significantly clarified the reason of the specificity of the peptide recognition sequence (i.e., Tyr2, Gly4 and Gln5 are indispensable for recognition).
  • the basic structure for recognition of the peptide antigen (the tag peptide of the present invention) by the antibody of the present invention was determined according to atomic coordinates.
  • the following (A) and (B) are made possible by use of protein engineering methods.
  • specific labeling can be achieved by modification of amino acid residues that are not responsible for tag recognition; and an additional complementary region is introduced into the antibody and the peptide by modification of amino acid residues at sites other than the core region for recognition and thereby antibodies that have a stronger binding capacity or can bind preferentially to a certain long peptide can be created.
  • the P20.1 antibody derived from the mouse-mouse hybridoma P20.1 (FERM BP-11061) is used not only as an antibody, but also as a reagent that can be recombinantly expressed and purified in a simple manner
  • the single chain Fv fragment (scFv) of the P20.1 antibody was prepared.
  • the expression construct shown in SEQ ID NO: 7 and Fig. 17 was prepared by use of the amino acid sequence of the P20.1 antibody variable region identified in the (5-1), and scFv expression was achieved by use of the pET11c vector and Escherichia coli BL21.
  • the scFv which was obtained as an inclusion body, was solubilized from insoluble fractions with guanidine hydrochloride, purified with Ni-NTA resin and refolded by sequential dialysis. As a result, about 2 mg of the scFv was obtained from 1L of the culture medium.
  • the binding strength of the scFv is weak because of the monovalence. For this reason, a recombinant protein fused with streptavidin downstream of the scFv was prepared for substantial improvement in affinity. This utilizes the property of streptavidin, i.e., tetramerization. Protein expression and purification were performed in the same manner as in the case of the scFv except for using the construct shown in Fig. 18 , to give a scFv tetramer (tetra-scFv).
  • the prepared scFv and tetra-scFv antibodies were examined for their peptide binding capacity with Biacore using a P4(20)-Fn-immobilized sensor chip.
  • the Fab fragment was used for the same examination as above.
  • the results of the Fab fragment, scFv antibody and tetra-scFv antibody are shown in Figs. 19 (a), (b) and (c) , respectively.
  • the scFv antibody showed almost the same binding activity as that of the Fab fragment and no decline in antigen binding capacity despite of a single chain.
  • the tetra-scFv antibody hardly dissociated and showed a strong binding capacity far beyond that of the original IgG molecule (P20.1 antibody).
  • tag peptide fusion proteins having a repeated sequence, specifically 1, 3 or 5 repeats of the P4 sequence were prepared (see the above (2-2)). These proteins were allowed to separately pass at a flow rate of 20 ⁇ L/min over the P20.1 antibody-immobilized sensor chip, and kinetics analysis was conducted using Biacore X-100 (GE Healthcare).
  • the results of the tagged fusion protein having 1 repeat of the P4 sequence are shown in Fig. 20 (a) .
  • the results of the tagged fusion protein having 3 repeats of the P4 sequence are shown in Fig. 20 (b) .
  • Fig. 20 (c) The results of the tagged fusion protein having 5 repeats of the P4 sequence are shown in Fig. 20 (c) .
  • the tagged fusion protein having only one repeat of the P4 sequence (Fig. 20 (a) ) showed an extremely weak affinity for the P20.1 antibody, while each of the tagged fusion proteins having multiple repeats of the P4 sequence showed a 4-fold or more strength in terms of the maximum binding capacity.
  • the P4x5 tag Fig. 20 (c) showed a further increased binding capacity, and this result makes it clear that such an increased effect depends on the repeat number of the P4 sequence (6 residues).
  • the anti-hGH monoclonal antibody HGH-B was immobilized to microtiter plates. After blocking, the supernatant of cells transiently expressing the hGH- ⁇ C-P4 fusion protein having P4 ⁇ 1, P4x3 or P4x5 linked thereto (see Fig. 3 , Fig. 4 and SEQ ID NO: 15) was added at various dilution ratios to wells of the plates, which were then allowed to stand at 4°C overnight. In this way, such a fusion protein was captured by the antibody on the plates. After washing, a biotinylated P20.1 antibody (5 ⁇ g/mL) was allowed to react with the fusion protein at room temperature for 30 minutes.
  • the P20.1 antibody was immobilized to microtiter plates at 10 ⁇ g/mL, and after blocking, the hGH- ⁇ C-P4 fusion protein was captured in the same manner as in the (7-2-1).
  • the results are shown in Fig. 22 .
  • tagged proteins having multiple repeats of the P4 sequence provide the ELISA system with a sufficient detection sensitivity as shown in Fig. 22 .
  • hGH- ⁇ C-P4 fusion proteins which have P4 ⁇ 1, P4 ⁇ 3 or P4 ⁇ 5, were separately expressed in HEK293T cells.
  • the fusion protein in the separate cell culture supernatant was quantified by the sandwich ELISA (which adopts a system of hGH antibody-mediated capture + anti-BAS serum-mediated detection, and is not dependent on the responsiveness to the P20.1 antibody) (before pull-down).
  • sandwich ELISA which adopts a system of hGH antibody-mediated capture + anti-BAS serum-mediated detection, and is not dependent on the responsiveness to the P20.1 antibody
  • 20 ⁇ L of the P20.1 antibody-Sepharose (bead form) was added, and then the mixture was allowed to react at 4°C for 1 hour.
  • the fusion protein in the supernatant was quantified by the sandwich ELISA (which adopts a system of hGH antibody-mediated capture + anti-BAS serum-mediated detection, and is not dependent on the responsiveness to the P20.1 antibody) (after pull-down).
  • the fusion protein purified with Ni-NTA agarose was used as a standard, and based on the standard curve, the fusion protein concentrations before and after pull-down by the P20.1 antibody were determined. The results are shown in Table 4. As is clear from Table 4, 3 to 5 repeats of the P4 sequence achieves the binding efficiency of about 80%.
  • the effluent obtained by each eluent was concentrated and then was subjected to SDS gel electrophoresis at an equal amount.
  • affinity binding was also performed using Ni-NTA beads on the same conditions as above, and the effluent obtained by use of imidazole as an eluent was analyzed simultaneously.
  • Fig. 23 (a) The results are shown in Fig. 23 (a) .
  • the above-mentioned numbers correspond to the lane numbers in Fig. 23 (a) .
  • "Ni" indicates the effluent from Ni-NTA beads.
  • the tagged fusion protein which was bound to the P20.1 antibody-Sepharose was not only eluted with 0.1 mg/mL or more of the P4(C8) peptide, but also completely eluted by combined use of propylene glycol and sodium chloride.
  • the tagged fusion protein was not eluted at all under some elution conditions often adopted in monoclonal antibody-based affinity chromatography (pH 2.2 acid conditions, chaotropic ions such as high-concentration iodide ion), and was only partially eluted under basic conditions of pH 11.5.
  • the results showed that the tag peptide fusion protein was eluted under mild conditions.
  • each effluent from P20.1 antibody beads contained no impurities, and this result proved that an extremely highly purified product can be obtained in a single step.
  • Fig. 23 (b) The results are shown in Fig. 23 (b) .
  • the above-mentioned numbers correspond to the lane numbers in Fig. 23 (b) . It is evident from the results shown in Fig. 23 (b) that a preferable concentration of propylene glycol is 40% or more, and that a high concentration of NaCl is not needed.
  • F-spondin which is a protein responsible for the axon guidance in the brain during the fetal period, was fused with the tag sequence P4x3, and the resulting fusion protein was purified with the P20.1 antibody-Sepharose.
  • the P4x3 sequence (18 residues) is attached to the downstream of the signal sequence of mouse nidogen, and further fused with the N-terminal 146-amino-acid domain of F-spondin via the TEV protease cleavage sequence (7 residues).
  • the base sequence at positions 901 to 1560 in the 6045-base DNA encoding the prepared recombinant F-spondin protein is shown in SEQ ID NO: 16 and Fig. 24 .
  • SEQ ID NO: 16 and Fig. 24 the base sequence at nucleotide positions 1 to 900 and 1561 to 6045 is omitted.
  • the amino acid sequence of the recombinant protein encoded by the DNA sequence of SEQ ID NO: 16 is shown in SEQ ID NOS: 16 and 17 and Fig. 24 .
  • the DNA sequence encoding F-spondin is described in, for example, Miyamoto et al. Arch. Biochem. Biophys. 390 (1), 93-100, 2001 .
  • the tag peptide/F-spondin fusion protein was transiently expressed in HEK293T cells by use of the above-mentioned construct, and 400 mL of the culture supernatant was collected one week later. This supernatant was allowed to adsorb onto 2 mL of the P20.1 antibody-Sepharose. Washing with TBS and eluting with a buffer solution containing 40% propylene glycol and 1 M NaCl were performed, and the resulting effluent was subjected to SDS gel electrophoresis. The results are shown in Fig. 25 . In Fig.
  • the lanes are as follows: lane 1: marker, lane 2: supernatant from transient expression cell culture, lanes 3 and 4: wash fractions, lanes 5 to 8: eluted fractions.
  • lane 1 marker
  • lane 2 supernatant from transient expression cell culture
  • lanes 3 and 4 wash fractions
  • lanes 5 to 8 eluted fractions.
  • Fig. 25 only the tag peptide/F-spondin fusion protein was specifically eluted with a buffer solution containing 40% propylene glycol and 1 M NaCl after adsorption onto the P20.1 antibody-Sepharose.
  • the purified F-spondin protein was concentrated and then subjected to crystallization screening. As a result, a good-quality single crystal was obtained under conditions using 0.1 M Tris (pH 8.5), 0.2 M trimethylamine n-oxide dihydrate and 20% PEG2000.
  • An enlarged image of the crystal of the purified F-spondin is shown in Fig. 26 .
  • the X ray crystal diffraction analysis of this crystal was conducted by Beamline AR-NW12A of High Energy Accelerator Research Organization and data at 1.85 ⁇ resolution were obtained. As shown in Fig. 27 , an extremely clear electron density map was obtained and the model building, which usually takes one day to several weeks, was completed in only 1 hour.
  • Reelin is a huge extracellular protein with a molecular weight of 400kDa or more and essential for development of the mammalian brain. No one in the world has succeeded in its purification due to its size and instability.
  • An expression construct for a fusion protein having the P4x3 tag attached to the N-terminus of reelin was prepared. This expression construct is shown in Fig. 28 .
  • the tag peptide/reelin fusion protein was transiently expressed in HEK293T cells by use of the construct shown in Fig. 28 and 800 mL of the culture supernatant was collected one week later.
  • the fusion protein was purified using the P20.1 antibody-Sepharose in the same manner as in the case of F-spondin, and finally about 30 ⁇ g of the fusion protein was obtained.
  • the results of SDS gel electrophoresis and western blotting of the obtained protein are shown in Fig. 29 .
  • R and NR represent reducing conditions and non-reducing conditions, respectively.
  • Fig. 29 R and NR represent reducing conditions and non-reducing conditions, respectively.
  • the fusion protein in SDS gel electrophoresis, was in a huge polymeric form with a molecular weight of 10 million or more under non-reducing conditions, while the main bands of 430kDa and 330kDa and some bands corresponding to 170kDa or less fragments were observed under reducing conditions.
  • the results of western blotting using an anti-reelin antibody and the P20.1 antibody showed that all these bands correspond to full length reelin or its partially degraded fragments, and that the recombinant reelin protein can be obtained with 95% or more purity in a single step.
  • Tag peptide/fibronectin fusion proteins which have the tag sequence having repeats of the 4-residue YPGQ (SEQ ID NO: 18), which is the minimum recognition unit for the P20.1 antibody, were prepared. Specifically, as shown in Fig. 30 , the construct for each fusion protein was named His-X(n)-Fn (wherein n is the repeat number), and 5 different constructs with 1 to 5 repeats were prepared. Escherichia coli BL21 (DE3) cells were transformed with these respective constructs described above, and induced expression of the corresponding tag peptide fusion proteins was achieved by a usual method. Each of the produced tag peptide/fibronectin fusion proteins was purified using Ni-NTA agarose. The electrophoresis image of the purified proteins is shown in Fig. 31 .
  • An expression construct for a tag peptide/GFPuv fusion protein which has the tag sequence P4x3 attached to the N-terminus of a fluorescence protein GFPuv, was prepared (see Fig. 33 ).
  • the insert was prepared by extension PCR and then was inserted into the NcoI-BamHI site of the expression vector pET16b (Novagen).
  • Escherichia coli BL21 (DE3) cells were transformed with this construct, induced expression of the corresponding tag peptide fusion protein was achieved by a usual method and Escherichia coli lysate was prepared.
  • the tag peptide, the tag peptide fusion protein and a monoclonal antibody produced by mouse-mouse hybridoma P20.1 having accession number FERM BP-11061 are useful for a system that enables recombinant proteins to be highly purified in an easy and inexpensive manner.
  • the purification method for proteins is useful as a method that enables recombinant proteins to be highly purified in an easy and inexpensive manner.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

  1. Peptide marqueur comprenant une séquence d'acides aminés représentée par la formule (I) suivante :

            X1-Tyr-X2-Gly-Gln-X3     (I)

    dans laquelle X1, X2 et X3 sont identiques ou différents et représentent chacun un quelconque résidu d'acide aminé, et
    ledit peptide marqueur comprenant une séquence d'acides aminés comportant 3 à 5 répétitions de Tyr-Pro-Gly-Gln (SEQ ID NO. : 18).
  2. Peptide marqueur selon la revendication 1, dans lequel X3 représente un acide aminé hydrophobe.
  3. Peptide marqueur selon la revendication 2, dans lequel l'acide aminé hydrophobe est la Val.
  4. Peptide marqueur selon l'une quelconque des revendications 1 à 3, qui consiste en une séquence d'acides aminés représentée par l'une quelconque des propositions (a) à (f) suivantes :
    (a) Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln ;
    (b) Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln ;
    (c) Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln ;
    (d) Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Val ;
    (e) Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Val ; ou
    (f) Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Tyr-Pro-Gly-Gln-Val.
  5. Protéine hybride de peptide marqueur comprenant le peptide marqueur selon l'une quelconque des revendications 1 à 4 lié à celle-ci.
  6. Polynucléotide codant pour le peptide marqueur selon l'une quelconque des revendications 1 à 4.
  7. Vecteur recombiné contenant le polynucléotide selon la revendication 6.
  8. Procédé de purification pour protéines comprenant les étapes (i) à (iii) suivantes :
    (i) une étape de préparation d'un mélange d'une protéine hybride de peptide marqueur comprenant le peptide marqueur selon l'une quelconque des revendications 1 à 4 et une autre substance ;
    (ii) une étape consistant à laisser agir un anticorps monoclonal, produit par un hybridome souris-souris P20.1 ayant le numéro d'enregistrement FERM BP-11061, sur le mélange obtenu à l'étape (i) et à former un complexe avec la protéine hybride de peptide marqueur ; et
    (iii) une étape consistant à laisser agir un solvant organique miscible à l'eau sur le complexe obtenu à l'étape (ii) pour libérer la protéine hybride de peptide marqueur de l'anticorps.
  9. Kit d'expression d'une protéine hybride de peptide marqueur comprenant le peptide marqueur selon l'une quelconque des revendications 1 à 4, comprenant le vecteur recombiné selon la revendication 7.
EP08871991.9A 2008-01-31 2008-12-18 Peptide marqueur et son utilisation Not-in-force EP2239267B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008020804 2008-01-31
PCT/JP2008/073069 WO2009096112A1 (fr) 2008-01-31 2008-12-18 Peptide marqueur et son utilisation

Publications (3)

Publication Number Publication Date
EP2239267A1 EP2239267A1 (fr) 2010-10-13
EP2239267A4 EP2239267A4 (fr) 2014-01-01
EP2239267B1 true EP2239267B1 (fr) 2016-10-12

Family

ID=40912471

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08871991.9A Not-in-force EP2239267B1 (fr) 2008-01-31 2008-12-18 Peptide marqueur et son utilisation

Country Status (5)

Country Link
US (1) US8975384B2 (fr)
EP (1) EP2239267B1 (fr)
JP (1) JP5257997B2 (fr)
CN (1) CN101970456B (fr)
WO (1) WO2009096112A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423218B1 (fr) * 2009-04-22 2014-06-11 Osaka University Peptide marqueur ayant une séquence de reconnaissance de protéase et son utilisation
JP2012140331A (ja) * 2010-12-28 2012-07-26 Tosoh Corp タグペプチド
KR101342974B1 (ko) 2012-11-06 2013-12-18 명지대학교 산학협력단 신규 펩티드 태그 및 이의 용도
JP6399563B2 (ja) 2014-12-24 2018-10-03 国立大学法人大阪大学 Ｗｎｔ蛋白質の製造方法および保存方法
US10513562B2 (en) 2016-11-09 2019-12-24 Fujifilm Wako Pure Chemical Corporation Fragment antibody and method for crystallizing protein using fragment antibody
EP3916009B1 (fr) * 2020-05-26 2023-06-28 Sartorius Lab Instruments GmbH & Co. KG Protéines recombinantes basées sur du fibrinogène

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9414580D0 (en) 1994-07-19 1994-09-07 Cancer Res Campaign Tech Materials and methods relating to the diagnosis of synovial sarcomas
JP2002504369A (ja) 1998-02-27 2002-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ活性化レセプター４およびその使用。
US6111075A (en) 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)
US7241580B2 (en) 2004-06-08 2007-07-10 Wisconsin Alumni Research Foundation Immunoaffinity chromatography using epitope tags to polyol-responsive monoclonal antibodies
CN101004417B (zh) 2007-01-11 2011-08-24 福建农林大学 基于单链抗体的脱氧雪腐镰刀菌烯醇检测方法及其试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT S HODGES ET AL: "Antigen-Antibody Interaction SYNTHETIC PEPTIDES DEFINE LINEAR ANTIGENIC DETERMINANTS RECOGNIZED BY MONOCLONAL ANTIBODIES DIRECTED TO THE CYTOPLASMIC CARBOXYL TERMINUS OF RHODOPSIN", 25 August 1988 (1988-08-25), pages 11768 - 11775, XP055203096, Retrieved from the Internet <URL:http://www.jbc.org/content/263/24/11768.full.pdf> [retrieved on 20150717] *

Also Published As

Publication number Publication date
JPWO2009096112A1 (ja) 2011-05-26
US20110039331A1 (en) 2011-02-17
CN101970456A (zh) 2011-02-09
EP2239267A1 (fr) 2010-10-13
US8975384B2 (en) 2015-03-10
CN101970456B (zh) 2014-11-26
JP5257997B2 (ja) 2013-08-07
EP2239267A4 (fr) 2014-01-01
WO2009096112A1 (fr) 2009-08-06

Similar Documents

Publication Publication Date Title
Burgess et al. Advances in gentle immunoaffinity chromatography
EP2239267B1 (fr) Peptide marqueur et son utilisation
US11098081B2 (en) Epitope tag and method for detection and/or purification of tagged polypeptides
US20220213447A1 (en) AAV9 Affinity Agents
CN113195516A (zh) 由特异性结合物识别的表位标签
US20230391829A1 (en) Aav8 affinity agents
US8481310B2 (en) Tag peptide having a protease recognition sequence and use thereof
US20240026344A1 (en) Affinity ligand libraries of three-helix bundle proteins and uses thereof
US20050118646A1 (en) Method for purification of a protein complex and identification of its components
WO2005121178A2 (fr) Chromatographie d&#39;immunoaffinite au moyen de marques epitopes pour des anticorps monoclonaux sensibles au polyol
US6986994B2 (en) INGAP displacement assays
CN113980127A (zh) 抗耐甲氧西林葡萄球菌的纳米抗体及其制备方法和用途
US20060110771A1 (en) Proteins capable of binding to female sex hormones and process for producing the same
US20240174717A1 (en) Affinity agents
WO2023122327A2 (fr) Ligands et agents d&#39;affinité dans le domaine chi
EP4453014A2 (fr) Ligands et agents d&#39;affinité dans le domaine chi
EP4337679A2 (fr) Peptides de mertk et leurs utilisations
WO2021155022A1 (fr) Atténuation des effets de concentration de la digestion d&#39;anticorps pour une couverture de séquence complète
WO1999065946A2 (fr) Preparation d&#39;anticorps se liant a des acides amines modifies apres traduction a l&#39;interieur de peptides
JP2012157353A (ja) 抗トリガーファクターモノクローナル抗体
JPH05184388A (ja) モノクローナル抗体、その製造法および用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121126

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101ALI20121120BHEP

Ipc: C07K 16/18 20060101ALI20121120BHEP

Ipc: G01N 33/68 20060101ALI20121120BHEP

Ipc: C07K 16/28 20060101ALI20121120BHEP

Ipc: C07K 7/06 20060101ALI20121120BHEP

Ipc: C12N 5/10 20060101ALI20121120BHEP

Ipc: G01N 33/531 20060101ALI20121120BHEP

Ipc: C12P 21/08 20060101ALI20121120BHEP

Ipc: C07K 7/08 20060101AFI20121120BHEP

Ipc: C12N 15/09 20060101ALI20121120BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/06 20060101ALI20130821BHEP

Ipc: C12P 21/08 20060101ALI20130821BHEP

Ipc: C07K 7/08 20060101AFI20130821BHEP

Ipc: C07K 19/00 20060101ALI20130821BHEP

Ipc: C12N 15/09 20060101ALI20130821BHEP

Ipc: C12N 5/10 20060101ALI20130821BHEP

Ipc: C07K 16/18 20060101ALI20130821BHEP

Ipc: G01N 33/68 20060101ALI20130821BHEP

Ipc: C07K 16/28 20060101ALI20130821BHEP

Ipc: G01N 33/531 20060101ALI20130821BHEP

DA4 Supplementary search report drawn up and despatched (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602008046841

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07K0004000000

Ipc: C07K0007080000

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20131128

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/06 20060101ALI20131122BHEP

Ipc: C07K 7/08 20060101AFI20131122BHEP

Ipc: C12N 15/09 20060101ALI20131122BHEP

Ipc: C07K 16/28 20060101ALI20131122BHEP

Ipc: C07K 5/107 20060101ALI20131122BHEP

Ipc: C12P 21/08 20060101ALI20131122BHEP

Ipc: G01N 33/531 20060101ALI20131122BHEP

Ipc: G01N 33/68 20060101ALI20131122BHEP

Ipc: C07K 16/18 20060101ALI20131122BHEP

Ipc: C12N 5/10 20060101ALI20131122BHEP

Ipc: C07K 1/22 20060101ALI20131122BHEP

Ipc: C07K 19/00 20060101ALI20131122BHEP

17Q First examination report despatched

Effective date: 20150722

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160622

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 836421

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008046841

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20161012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 836421

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170112

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170212

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170213

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008046841

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170112

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

26N No opposition filed

Effective date: 20170713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161218

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161218

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20081218

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181127

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20181123

Year of fee payment: 11

Ref country code: FR

Payment date: 20181123

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008046841

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191218

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200701